CoughingNCT07694284
A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being
A study testing Super Lungs Liquid Drops in people with Coughing and Throat Irritation, run by SuperBonsai Inc. at 1 site in United States.
Trial summary
This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Coughing, Throat Irritation
- What is being tested?
- Super Lungs Liquid Drops
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jul 2026to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 18-65 years.
- Over the past two months, has experienced bothersome coughing on a weekly basis.
- Anyone who has experienced issues with at least two of the following over the past four weeks: chest tightness or congestion; persistent throat irritation or itchiness; excess mucus or phlegm buildup.
- Generally healthy, without any uncontrolled chronic disease.
- Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
- Resides in the United States.
- Has access to the internet and a device (smartphone, tablet, or computer) capable of completing online questionnaires.
- Willing to follow the study protocol and complete all required assessments.
Who cannot join
- Anyone with a known allergy or sensitivity to any of the study product ingredients.
- Anyone with a known allergy to plants in the Asteraceae/Compositae family.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- Anyone currently taking immunosuppressant medications (e.g., cyclosporine, methotrexate, biologics such as adalimumab or infliximab).
- Anyone with a diagnosed autoimmune disorder (e.g., lupus, rheumatoid arthritis, multiple sclerosis).
- Anyone with uncontrolled hypertension or currently taking antihypertensive medications, diuretics, or corticosteroids.
Show all 10Show fewer
- Anyone currently taking anticoagulant or antiplatelet medications (e.g., warfarin, heparin, clopidogrel).
- Anyone with a chronic health condition that could impact their participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
- Anyone with a history of alcohol use disorder or currently in alcohol recovery.
- Anyone currently participating in another research study or who plans to participate in another study during the study period. (
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. All 35 enrolled participants will receive the active study product and self-administer 2 mL of the drops daily (two full droppers of 1 mL each, once daily with the first meal of the day) for 12 weeks.
- Conditions
- Coughing, Throat Irritation
- Being tested
- Super Lungs Liquid Drops
- Keywords
- Airway Soothing, Respiratory Comfort
- Medical subject headings
- Cough
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Super Lungs Liquid DropsDietary supplement
All 35 participants receive Super Lungs Liquid Drops at 2 mL daily (two full droppers of 1 mL each), administered once daily with the first meal of the day, for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Super Lungs Liquid Drops | Experimental | Not described Receives: Dietary Supplement: Super Lungs Liquid Drops |
What is being measured
The primary outcome is the main question the study is designed to answer.
Respiratory comfort
Change in self-reported respiratory comfort assessed by questionnaires.
Measured: Baseline, Week 2, Week 4, Week 8, and Week 12
Normal airway function
Change in self-reported normal airway function assessed by questionnaires.
Measured: Baseline, Week 2, Week 4, Week 8, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2026
- Study start2 Jul 2026
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CoughingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SuperBonsai Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07694284
- Sponsor's protocol ID
- SUPER-81411
- Status last verified
- Jul 2026
- First submitted
- 2 Jul 2026
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being
- ClinicalTrials.gov ID
- NCT07694284
- Acronym / sponsor ID
- SUPER-81411
- Conditions
- Coughing, Throat Irritation
- Keywords
- Airway Soothing, Respiratory Comfort
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- SuperBonsai Inc.Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 2 Jul 2026 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 9 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. All 35 enrolled participants will receive the active study product and self-administer 2 mL of the drops daily (two full droppers of 1 mL each, once daily with the first meal of the day) for 12 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Super Lungs Liquid Drops | Experimental | Dietary Supplement: Super Lungs Liquid Drops |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Adults aged 18-65 years.
- Over the past two months, has experienced bothersome coughing on a weekly basis.
- Anyone who has experienced issues with at least two of the following over the past four weeks: chest tightness or congestion; persistent throat irritation or itchiness; excess mucus or phlegm buildup.
- Generally healthy, without any uncontrolled chronic disease.
- Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
Key exclusion criteria (10 listed)
- Anyone with a known allergy or sensitivity to any of the study product ingredients.
- Anyone with a known allergy to plants in the Asteraceae/Compositae family.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- Anyone currently taking immunosuppressant medications (e.g., cyclosporine, methotrexate, biologics such as adalimumab or infliximab).
- Anyone with a diagnosed autoimmune disorder (e.g., lupus, rheumatoid arthritis, multiple sclerosis).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Super Lungs Liquid DropsAll 35 participants receive Super Lungs Liquid Drops at 2 mL daily (two full droppers of 1 mL each), administered once daily with the first meal of the day, for 12 weeks. | Dietary supplement | Super Lungs Liquid Drops |
Primary outcome
Respiratory comfort
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change in self-reported respiratory comfort assessed by questionnaires.
Normal airway function
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change in self-reported normal airway function assessed by questionnaires.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coughing
RecruitingPhase 2
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
Refractory Chronic Cough
RecruitingObservational study
Physical Impairments in Premature Ventricular Complex
Premature Ventricular Complexes
RecruitingObservational study
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
Cough
Not yet recruiting
High-Flow Nasal Oxygen-Assisted Deep Extubation Versus Awake Extubation in Morbidly Obese Patients
Deep Tracheal Extubation
Recruiting
Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer
Head and Neck Cancers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Super Lungs Liquid Drops in people with Coughing and Throat Irritation, run by SuperBonsai Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Respiratory comfort (time frame: Baseline, Week 2, Week 4, Week 8, and Week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.